FDA (U.S. Food and Drug Administration). 2010. Guidance for industry: Qualification process for drug development tools. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf (accessed September 1, 2011).
FHCRC (Fred Hutchinson Cancer Research Center). 2011. Cancer Immunotherapy Trials Network (CITN). http://www.fhcrc.org/science/vidd/programs/citn/index.html (accessed September 1, 2011).
FNIH (Foundation for the National Institutes of Health). 2010. The Biomarkers Consortium Launches I-SPY 2 breast cancer clinical trial. http://www.fnih.org/work/key-initiatives-0/i-spy-2-investigation-serial-studies-predict-your-therapeutic-response (accessed September 1, 2011).
FNIH. 2011a. Our work: Working toward a healthier world. http://www.fnih.org/work (accessed September 1, 2011).
FNIH. 2011b. Policies and procedures. http://www.biomarkersconsortium.org/policies.php (accessed September 1, 2011).
FTC (Federal Trade Commission) and DOJ. 2000. Antitrust guidelines for collaborations among competitors. http://www.ftc.gov/os/2000/04/ftcdojguidelines.pdf (accessed September 29, 2011).
Grupp, S. A., and C. H. June. 2011. Adoptive cellular therapy. In Cancer immunology and immunotherapy, edited by G. Dranoff. Heidelberg: Springer.
HHS (U.S. Department of Health and Human Services). 2011. Human subjects research protections: Enhancing protections for research subjects and reducing burden, delay, and ambiguity for investigators. Federal Register 76(143):44512–44531.
Hsieh, A. C., and M. M. Moasser. 2007. Targeting HER proteins in cancer therapy and the role of the non-target HER3. British Journal of Cancer 97(4):453–457.
Infante, J. R., G. S. Falchook, D. P. Lawrence, J. S. Weber, R. F. Kefford, J. C. Bendell, R. Kurzrock, G. Shapiro, R. R. Kudchadkar, G. V. Long, H. A. Burris, K. B. Kim, A. Clements, S. Peng, B. Yi, A. J. Allred, D. Ouellet, K. Patel, P. F. Lebowitz, and K. T. Flaherty. 2011. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). Journal of Clinical Oncology 29(15S):CRA8503.
IOM (Institute of Medicine). 2010a. Extending the spectrum of precompetitive collaboration in oncology research: Workshop summary. Washington, DC: The National Academies Press.
IOM. 2010b. A national cancer clinical trials system for the 21st century: Reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press.
Kim, E. S., R. S. Herbst, J. J. Lee, G. R. Blumenschein, Jr., A. Tsao, C. M. Alden, X. Tang, S. Liu, D. J. Stewart, J. V. Heymach, H. T. Tran, M. E. Hicks, J. Erasmus, Jr., S. Gupta, G. Powis, S. M. Lippman, I. I. Wistuba, and W. K. Hong. 2010. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): Personalizing therapy for lung cancer. Paper presented at AACR 101st Annual Meeting, Washington, DC.
Kim, E. S., R. S. Herbst, I. I. Wistuba, J. J. Lee, G. R. Blumenschein, Jr., A. Tsao, D. J. Stewart, M. E. Hicks, J. Erasmus, Jr., S. Gupta, C. M. Alden, S. Liu, X. Tang, F. R. Khuri, H. T. Tran, B. E. Johnson, J. V. Heymach, L. Mao, F. Fossella, M. S. Kies, V. Papadimitrakopoulou, S. E. Davis, S. M. Lippman, and W. K. Hong. 2011. The BATTLE Trial: Personalizing therapy for lung cancer. Cancer Discovery 1(1):44–53.
Kim, P. S., and R. Ahmed. 2010. Features of responding T Cells in cancer and chronic infection. Current Opinion in Immunology 22(2):223–230.
Mayfield, E. 2011. Combining targeted cancer therapies: Much promise, many hurdles. NCI Cancer Bulletin 8(10):6.
Munos, B. 2009. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8(12):959–968.